p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12.
about
The roles of mesenchymal stem cells in tumor inflammatory microenvironmentSecondary mutations as mediators of resistance to targeted therapy in leukemiaThe Cytokinome Profile in Patients with Hepatocellular Carcinoma and Type 2 DiabetesHuman extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironmentHigh Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia.MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth.Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia.Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphomaInhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.The regulation of normal and leukemic hematopoietic stem cells by niches.Histone Deacetylase Inhibitors Target the Leukemic Microenvironment by Enhancing a Nherf1-Protein Phosphatase 1α-TAZ Signaling Pathway in OsteoblastsPreclinical activity of the novel B-cell-specific Moloney murine leukemia virus integration site 1 inhibitor PTC-209 in acute myeloid leukemia: Implications for leukemia therapySynergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia.Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang.HIF-1α and GLUT-1 Expression in Atypical Endometrial Hyperplasia, Type I and II Endometrial Carcinoma: A Potential Role in Pathogenesis.Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cellsPunicalagin, a polyphenol in pomegranate juice, downregulates p53 and attenuates hypoxia-induced apoptosis in cultured human placental syncytiotrophoblasts.Leukemia cells induce changes in human bone marrow stromal cells.Effects of hypoxia and HIFs on cancer metabolism.FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia.CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks.Mechanisms of tumor cell resistance to the current targeted-therapy agents.Induction of p53 suppresses chronic myeloid leukemia.Upregulation of SOCS-1 by Nutlin-3 in acute myeloid leukemia cells but not in primary normal cells.A novel three-dimensional stromal-based model for in vitro chemotherapy sensitivity testing of leukemia cells.Treatment of Relapsed/Refractory Acute Myeloid Leukemia.Predicting Chemotherapy Resistance in AML.Selective induction of TP53I3/p53-inducible gene 3 (PIG3) in myeloid leukemic cells, but not in normal cells, by Nutlin-3.Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment.Mitochondrial stress-induced p53 attenuates HIF-1α activity by physical association and enhanced ubiquitination.Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular MechanismsDysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia.Focal Adhesion Kinase as a Potential Target in AML and MDS.Basal p53 expression is indispensable for mesenchymal stem cell integrity.Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.Oroxylin A reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12/CXCR7 axis in bone marrow microenvironment.Role of MSC-derived galectin 3 in the AML microenvironment.
P2860
Q26823759-D9F93BBF-7D42-4E4C-90D8-10BD01BF5786Q28087213-FCC7A50B-3B27-45B7-B5C5-C6F6321B5DC3Q28546913-4596B594-63AB-4662-824C-DF56BF419077Q30514797-74BDFC1C-80EB-4ED4-8718-6A290D8284C4Q33572309-B0880A9F-8CCF-40ED-9A83-B3BEE504B20FQ34899627-19D5D5E6-131D-485D-8E04-716A5AC22737Q35178411-F1853BAA-6BCE-45AA-86F5-2041865DFF77Q35742364-8E1414A7-9D3C-4EA9-B134-51557293AFB1Q35859229-A2EDF0B2-9FFD-4D05-91E6-54F26D711DB4Q36284911-587B6FB2-FE8B-4AD1-BAA8-65088D413998Q36444091-7864A014-B635-4FC8-AF50-A9968774CF59Q36467373-E7C4D0DF-9ACF-4521-9B2B-44548F324AAAQ36544358-AB5F2BCB-3E8E-4C3B-8216-9A22398F88FFQ36734163-AB14A7AD-DB52-40F3-A611-2A481E3C088FQ36891005-951928C4-4C42-4767-A103-738C45189B72Q37094051-74887987-53A6-4589-A0FD-9C8475EE1A4CQ37102611-CDA8106D-6F77-47A4-A633-CE32AB4F5127Q37114045-7335A648-E5BD-4A1E-9167-05DC17A599B6Q37341983-007C1F05-BD36-4FCA-A118-E19814120FA0Q37441710-DEC1FBFB-18F5-4794-9C92-59A73DC7D503Q38005965-5535DD96-00D5-4C58-9428-1F5DE3EC2823Q38026453-CA466001-94AB-482C-915D-4F6B5C99EE23Q38472331-6BA4D2F6-49AE-4E62-AA6A-F2F438D85ED6Q38828353-0A83AABF-B25C-4849-BC4C-5E9734DB56AAQ39022440-9C304C0C-22AA-4067-949E-85387517E6A5Q39029498-DE3F98BD-3019-4A00-8DDB-6007C6F40FECQ39169570-AA10F74F-BAF4-4593-99A8-AFC0AE75E452Q39175665-BF51FE9A-BF4E-47BE-B12D-6DDD8890CEFEQ39233284-12E14791-6466-4F9B-AB19-20347CF5647FQ39236172-76DF4553-FFCD-4CA5-915C-49176E30D890Q39411949-87A1D162-8EAD-4917-8D34-4670F1086A15Q40030805-13F1B667-1077-4CEF-91CD-17B991A6E363Q42262053-7800D194-F87B-4A58-BC3C-31F931C80785Q44176860-AE792E80-E00F-4F8F-B950-E3ACA1D8E2CFQ45120868-6576587C-C0DC-40D2-9F2A-27C1D14277CBQ46471789-60CFE790-5F13-4C5C-857E-0BF043C85365Q47222566-955EC703-F552-4CD8-8000-DAB243E8A78FQ47965108-76D88378-B19B-474E-B09B-CDDFD6F063E0Q51566420-B47DFF25-97B9-4BF1-8199-1F42CD7BFEFEQ52588202-FAFF1D42-66EC-46EC-A14A-3A17F019D025
P2860
p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
p53 activation of mesenchymal ...... ted down-regulation of CXCL12.
@ast
p53 activation of mesenchymal ...... ted down-regulation of CXCL12.
@en
type
label
p53 activation of mesenchymal ...... ted down-regulation of CXCL12.
@ast
p53 activation of mesenchymal ...... ted down-regulation of CXCL12.
@en
prefLabel
p53 activation of mesenchymal ...... ted down-regulation of CXCL12.
@ast
p53 activation of mesenchymal ...... ted down-regulation of CXCL12.
@en
P2093
P2860
P1433
P1476
p53 activation of mesenchymal ...... ted down-regulation of CXCL12.
@en
P2093
Elizabeth Shpall
Kensuke Kojima
Naoki Shinojima
Rodrigo Jacamo
Teresa McQueen
Xuelin Huang
P2860
P304
P356
10.1182/BLOOD-2011-02-334136
P407
P577
2011-08-25T00:00:00Z